PRM vs. ABDX, GENI, LLAI, VRCI, IHC, KNB, INHC, CHLL, FDBK, and CNSL
Should you be buying Proteome Sciences stock or one of its competitors? The main competitors of Proteome Sciences include Abingdon Health (ABDX), GENinCode (GENI), LungLife AI (LLAI), Verici Dx (VRCI), Inspiration Healthcare Group (IHC), Kanabo Group (KNB), Induction Healthcare Group (INHC), Chill Brands Group (CHLL), Feedback (FDBK), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical" sector.
Proteome Sciences (LON:PRM) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
In the previous week, Abingdon Health had 3 more articles in the media than Proteome Sciences. MarketBeat recorded 3 mentions for Abingdon Health and 0 mentions for Proteome Sciences. Proteome Sciences' average media sentiment score of 0.00 beat Abingdon Health's score of -0.23 indicating that Proteome Sciences is being referred to more favorably in the media.
Abingdon Health has a net margin of -41.82% compared to Proteome Sciences' net margin of -48.59%. Proteome Sciences' return on equity of 0.00% beat Abingdon Health's return on equity.
Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.
Proteome Sciences received 162 more outperform votes than Abingdon Health when rated by MarketBeat users.
23.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 10.6% of Abingdon Health shares are held by institutional investors. 19.5% of Proteome Sciences shares are held by company insiders. Comparatively, 56.1% of Abingdon Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Proteome Sciences has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Abingdon Health has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500.
Summary
Abingdon Health beats Proteome Sciences on 7 of the 13 factors compared between the two stocks.
Get Proteome Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Proteome Sciences Competitors List
Related Companies and Tools
